Ten University of California startups are hoping to open 2021 with a bang by securing one of two $50,000 prizes at the GCV Digital Forum next month.

Biopharmaceutical company Origenis helped form the neurological and immunological disease drug developer, which has revealed series A and B funding.

The clinical data management platform boosted its total funding to $30m in a Centene-led series B round featuring Optum Ventures.

Kaiser Foundation Hospitals and Lilly Asia Ventures backed a round for the pharmaceutical research services provider that was led by Fidelity.

Novo's Repair Impact Fund and Sanofi Ventures were among the investors in a $57.6m round that will fund work on MinervaX's group B Streptococcus vaccine.

General Electric's healthcare technology subsidiary is partnering Wayra UK on a scheme focusing on artificial intelligence-equipped healthtech startups.

Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.

The UBC-linked antibody drug developer has added $73m to its initial public offering, and its shares are still trading at more than double the IPO price.

The Eli Lilly-backed antibody drug developer has added $73m to its initial public offering, and its shares are still trading at more than double the IPO price.

University of Florida has backed a second round for Atsena, a vision loss therapy developer exploiting inventions the institution had originally licensed to Sanofi.